These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23546445)

  • 21. [Cardioprotective effect of aldosterone antagonists for ventricular remodeling].
    Tatsumi T; Matsubara H
    Nihon Rinsho; 2006 Jul; 64 Suppl 5():524-9. PubMed ID: 16897886
    [No Abstract]   [Full Text] [Related]  

  • 22. Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF study.
    Jacobshagen C; Belardinelli L; Hasenfuss G; Maier LS
    Clin Cardiol; 2011 Jul; 34(7):426-32. PubMed ID: 21538388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Active and Passive Components of LV Diastolic Filling With Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: Mechanistic Insights From Spironolactone Response.
    Kosmala W; Przewlocka-Kosmala M; Marwick TH
    JACC Cardiovasc Imaging; 2019 May; 12(5):784-794. PubMed ID: 29248640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [2 promising substances for diastolic heart failure].
    Einecke D
    MMW Fortschr Med; 2012 Sep; 154(15):22. PubMed ID: 22997932
    [No Abstract]   [Full Text] [Related]  

  • 25. Aldosterone as a target in congestive heart failure.
    Rajagopalan S; Pitt B
    Med Clin North Am; 2003 Mar; 87(2):441-57. PubMed ID: 12693733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aldosterone-receptor antagonists in heart failure: insights after EMPHASIS-HF.
    Jacob MS; Tang WH
    Curr Heart Fail Rep; 2011 Mar; 8(1):7-13. PubMed ID: 21207206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spironolactone made no difference to patients with mild diastolic heart failure.
    BMJ; 2013 Feb; 346():f1290. PubMed ID: 23447350
    [No Abstract]   [Full Text] [Related]  

  • 28. What constitutes optimal neurohumoral antagonism in chronic heart failure?
    Tajik AA; Dickstein K
    Heart; 2016 Dec; 102(23):1922-1932. PubMed ID: 27742799
    [No Abstract]   [Full Text] [Related]  

  • 29. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure.
    Suzuki G; Morita H; Mishima T; Sharov VG; Todor A; Tanhehco EJ; Rudolph AE; McMahon EG; Goldstein S; Sabbah HN
    Circulation; 2002 Dec; 106(23):2967-72. PubMed ID: 12460880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension.
    Tsujimoto T; Kajio H
    J Am Heart Assoc; 2020 Dec; 9(23):e018827. PubMed ID: 33222584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction.
    Weir RA; Tsorlalis IK; Steedman T; Dargie HJ; Fraser R; McMurray JJ; Connell JM
    Eur J Heart Fail; 2011 Dec; 13(12):1305-13. PubMed ID: 21940729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?
    Mitter SS; Shah SJ
    Curr Atheroscler Rep; 2015 Nov; 17(11):64. PubMed ID: 26408016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial.
    Lewis EF; Claggett B; Shah AM; Liu J; Shah SJ; Anand I; O'Meara E; Sweitzer NK; Rouleau JL; Fang JC; Desai AS; Retta TM; Solomon SD; Heitner JF; Stamos TD; Boineau R; Pitt B; Pfeffer MA
    Circ Heart Fail; 2018 Mar; 11(3):e004457. PubMed ID: 29664406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MY APPROACH to the patient with heart failure and improved ejection fraction
    Cohn JN
    Trends Cardiovasc Med; 2018 Feb; 28(2):153. PubMed ID: 29032935
    [No Abstract]   [Full Text] [Related]  

  • 35. Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction.
    Rossignol P; Claggett BL; Liu J; Vardeny O; Pitt B; Zannad F; Solomon S
    Am J Hypertens; 2018 Mar; 31(4):407-414. PubMed ID: 29228101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aldosterone blockade in patients with acute myocardial infarction.
    Pitt B
    Circulation; 2003 May; 107(20):2525-7. PubMed ID: 12777314
    [No Abstract]   [Full Text] [Related]  

  • 37. [Heart failure with preserved ejection fraction (HFpEF)].
    Tschöpe C
    MMW Fortschr Med; 2015 Mar; 157(5):45-8. PubMed ID: 26015012
    [No Abstract]   [Full Text] [Related]  

  • 38. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure.
    George J; Struthers AD
    Expert Opin Pharmacother; 2007 Dec; 8(17):3053-9. PubMed ID: 18001264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aldosterone antagonism and myocardial infarction: from animals to man and back.
    Solomon SD; Pfeffer MA
    J Am Coll Cardiol; 2003 Nov; 42(9):1674-6. PubMed ID: 14607458
    [No Abstract]   [Full Text] [Related]  

  • 40. Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT.
    Patel RB; Shah SJ; Fonarow GC; Butler J; Vaduganathan M
    Curr Heart Fail Rep; 2017 Aug; 14(4):217-222. PubMed ID: 28647918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.